HC Wainwright & Co. Reiterates Buy on PDS Biotechnology, Maintains $7 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 91.1%

Neg 0% Neu 91.1% Pos 0%

HC Wainwright & Co. analyst Joseph Pantginis reiterates PDS Biotechnology (NASDAQ:PDSB) with a Buy and maintains $7 price target.